Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Recent News

• June 8, 2009
  Threshold Pharmaceuticals ASCO Webcast Available On Company Website
• May 30, 2009
  Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors
• May 27, 2009
  Threshold Pharmaceuticals Announces a Presentation at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
• May 7, 2009
  Threshold Pharmaceuticals Reports First Quarter 2009 Financial Results
• April 20, 2009
  Threshold Pharmaceuticals Presents Positive TH-302 Preclinical Results in Three Scientific Presentations At AACR Annual Meeting
• April 14, 2009
  Threshold Pharmaceuticals Announces Multiple Presentations at the 2009 American Association for Cancer Research (AACR) Annual Meeting
• March 19, 2009
  Threshold Pharmaceuticals Announces Going Concern Opinion
• March 11, 2009
  Threshold Pharmaceuticals Announces Upcoming Presentation On TH-302 At the New York Academy of Sciences Hypoxia Meeting
• March 5, 2009
  Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
• February 5, 2009
  Threshold to Present At BIO CEO & Investor Conference On February 9

Company Events

May 31, 2009 - View Investor Presentation Webcast
American Society of Clinical Oncology (ASCO) Annual Meeting

April 18 - 22, 2009
American Association for Cancer Research (AACR) Annual Meeting

March 14, 2009
New York Academy of Sciences Conference: Hypoxia and Consequences